[Ruxolitinib, disseminated tuberculosis and primary myelofibrosis: A case study]
{{output}}
Introduction: Ruxolitinib is a Janus kinase 2 inhibitor (JAK2i) used in patients with primary myelofibrosis. This treatment is a risk factor for bacterial and viral infections, and can reactivate latent infections, such as tuberc... ...
